Reuters logo
BRIEF-Regenxbio says IND active for Phase I trial of RGX-314
February 14, 2017 / 12:27 PM / 10 months ago

BRIEF-Regenxbio says IND active for Phase I trial of RGX-314

Feb 14 (Reuters) - Regenxbio Inc

* Regenxbio announces IND active for Phase I trial of RGX-314 to treat wet age-related macular degeneration Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below